Emergent BioSolutions (EBS) Free Cash Flow (2010 - 2026)

Emergent BioSolutions' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$36.2 million for Q1 2026.

• In Q1 2026, Free Cash Flow fell 185.04% year-over-year to -$36.2 million; the TTM figure through Mar 2026 stood at $145.5 million (up 23.83% YoY), while the FY2025 annual figure was $169.0 million, up 197.54% from the prior year.
• Free Cash Flow was -$36.2 million for Q1 2026 at Emergent BioSolutions, down from $86.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $175.6 million in Q4 2022 to a low of -$191.8 million in Q1 2023.
• Historically, Free Cash Flow has averaged -$6.6 million across 5 years, with a median of -$12.7 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Free Cash Flow tumbled 678.64% in 2024, then surged 207.23% in 2025.
• A 5-year view of Free Cash Flow shows it stood at $175.6 million in 2022, then plunged by 105.87% to -$10.3 million in 2023, then sank by 678.64% to -$80.2 million in 2024, then soared by 207.23% to $86.0 million in 2025, then sank by 142.09% to -$36.2 million in 2026.
• The last three Free Cash Flow figures came in at -$36.2 million (Q1 2026), $86.0 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.